北京神州细胞生物技术集团股份公司 关于2025年度向特定对象发行股票申请获得 中国证券监督管理委员会同意注册批复的公告

Core Viewpoint - Beijing Sinocell Biotechnology Group Co., Ltd. has received approval from the China Securities Regulatory Commission for its application to issue shares to specific investors for the year 2025 [1][3]. Group 1 - The company has been granted registration approval for the issuance of shares to specific investors, as per the approval document issued by the China Securities Regulatory Commission [1]. - The issuance must strictly follow the declaration documents and issuance plan submitted to the Shanghai Stock Exchange [2]. - The approval is valid for 12 months from the date of registration consent, and the company must report any significant events to the Shanghai Stock Exchange before the issuance is completed [3]. Group 2 - The company’s board will handle the issuance matters within the stipulated timeframe and fulfill information disclosure obligations as required by the approval document and relevant laws [3]. - Contact information for the company and its sponsor (lead underwriter) is provided for investor inquiries [4]. - The announcement was made by the board of directors of Beijing Sinocell Biotechnology Group Co., Ltd. on January 6, 2026 [5].